Abstract
Triple Negative Breast Cancer (TNBC) is difficult to treat since it lacks the three most commonly targeted hormone receptors. Patients with TNBC are treated with platinum core chemotherapeutics, such as Cisplatin. However, despite the anticancer effects of Cisplatin, TNBC attenuates its effect and develops a resistance eventually, which results in tumor reoccurrence. Hence, there is a critical demand for effective alternative and natural ways to treat TNBC. Towards this, inhibiting TNBC cell proliferation by blocking the key glycolytic enzyme Lactase Dehydrogenase B (LDHB) is one viable option studied in this research. Galloflavin (GF), a potent LDHB inhibitor synthesized from gallic acid, is utilized in this research. In addition, Electrochemotherapy (ECT), which involves the application of electrical pulses (EP), was utilized to enhance GF uptake. MDA-MB-231, human TNBC cells were used for this, with/out Galloflavin, and eight pulses of 600V/cm, 800V/cm, 1000V/cm, and 1200V/cm, at 100μs and 1Hz. The cells were characterized using various assays, including viability, colony-forming, and reactive oxygen species (ROS). Results indicate a TNBC cell viability of as low as 22%, demonstrating the potential of this novel treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.